pharma Β· Asthma Β· Type 2 Diabetes
AstraZeneca
AstraZeneca trial registry β 142 ClinicalTrials.gov studies with program phase, status, and indication context.
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 129
- Drugs
- 77
- Patents
- 25
AstraZeneca clinical trials
Registry index of 142 ClinicalTrials.gov studies linked to AstraZeneca programs β each row shows trial ID, program name, phase, status, and indication.
AstraZeneca trial registry β 142 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for AstraZeneca.
-
D1447C00001 β Phase 3
Clinical update -
D6402C00012 β Phase 3
Clinical update -
D6405C00002 β Phase 2
Clinical update -
D3612L00005 β Phase 3
Clinical update -
D9311L00001 β Approved
Clinical update -
Trastuzumab Deruxtecan β Phase 3
Clinical update -
Trastuzumab Deruxtecan β Phase 3
Clinical update -
Trastuzumab deruxtecan β Phase 3
Clinical update
Trial registry
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β - NCT00542880CT.gov β
Symbicort Turbuhaler (budesonide/formoterol) 320/9 ΞΌg
Chronic Obstructive Pulmonary Disease (COPD)
-
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β - NCT01572792CT.gov β
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
Chronic Obstructive Pulmonary Disease
-
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β - NCT02207530CT.gov β
MEDI4736
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
-
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β - NCT04639219CT.gov β
Trastuzumab deruxtecan
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
-
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β - NCT07509151CT.gov β
Surovatamig
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
-
CT.gov β